Related Experiment Video

Updated: Jan 23, 2026

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

13.9K

Canagliflozin for Japanese patients with chronic heart failure and type II diabetes

Akira Sezai1, Hisakuni Sekino2, Satoshi Unosawa3

  • 1Department of Cardiovascular Surgery, Nihon University School of Medicine, 30-1 Oyaguchi-kamimachi, Itabashi-ku, Tokyo, 173-8610, Japan. asezai.med@gmail.com.

Cardiovascular Diabetology
|June 7, 2019
PubMed

Insights

Canagliflozin significantly reduced fat areas, improved cardiac and renal function, and enhanced endothelial function in patients with type II diabetes and chronic heart failure.

Area of Science:

  • Cardiology
  • Endocrinology
  • Metabolic Diseases

Background:

  • Sodium glucose cotransporter 2 inhibitors (SGLT2i) show cardiovascular benefits in diabetic patients.
  • Canagliflozin is an SGLT2 inhibitor studied for its effects in heart failure.

Purpose of the Study:

  • To evaluate the effects of canagliflozin in Japanese patients with chronic heart failure and type II diabetes.
  • To assess changes in fat areas, cardiac and renal markers, and endothelial function.

Main Methods:

  • A 12-month study involving 35 Japanese patients with chronic heart failure and type II diabetes treated with canagliflozin.
  • Primary endpoint: changes in fat areas (subcutaneous, visceral, total) via computed tomography.
  • Secondary endpoints: glycemic control, renal function, oxidative stress, lipids, natriuretic peptides (ANP, BNP), flow-mediated dilation (FMD), and echocardiographic function.

Main Results:

  • Significant reductions in all measured fat areas were observed at 12 months.
  • Significant decreases in ANP and BNP levels, improvements in renal function, oxidized LDL, and diastolic function (E/e') were noted.
  • Significant improvement in flow-mediated dilation (FMD) indicated enhanced endothelial function.

Conclusions:

  • Canagliflozin demonstrated cardiac and renal protective effects in patients with type II diabetes and chronic heart failure.
  • The drug improved oxidative stress, diastolic function, and endothelial function.
  • Canagliflozin may be a potential first-line therapy for patients with diabetes and heart failure with preserved ejection fraction.
Abstract

Keywords:
DiabetesHeart failureSGLT2 inhibitor

More Related Videos

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

1.1K
Integration of Brain Tissue Saturation Monitoring in Cardiopulmonary Exercise Testing in Patients with Heart Failure04:20

Integration of Brain Tissue Saturation Monitoring in Cardiopulmonary Exercise Testing in Patients with Heart Failure

Published on: October 1, 2019

6.2K

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
798
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.1K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
737
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
280
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
830
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
232